Edition:
United Kingdom

Jiangsu Hengrui Medicine Co Ltd (600276.SS)

600276.SS on Shanghai Stock Exchange

64.13CNY
14 Nov 2018
Change (% chg)

-- (--)
Prev Close
¥64.13
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
21,684,810
52-wk High
¥83.29
52-wk Low
¥48.85

Latest Key Developments (Source: Significant Developments)

Jiangsu Hengrui Medicine Says 9-Month Net Profit Up 25.1 Percent Y/Y
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::SAYS 9-MONTH NET PROFIT UP 25.1 PERCENT Y/Y.  Full Article

Jiangsu Hengrui Medicine's H1 Net Profit Up 21.4 Percent Y/Y At 1.9 Billion Yuan
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::SAYS H1 NET PROFIT UP 21.4 PERCENT Y/Y AT 1.9 BILLION YUAN ($278.34 million).  Full Article

Jiangsu Hengrui Medicine to merge with wholly owned medicine unit
Thursday, 12 Jul 2018 

July 12 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it will merge with a Jiangsu-based wholly owned medicine unit .Says the unit will be dissolved after merger .  Full Article

Jiangsu Hengrui Medicine passes FDA approval
Monday, 21 May 2018 

May 21(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it received approval for fondaparinux sodium injection (product) from U.S Food and Drug Administration .Company will be able to sell the product in the U.S. after receiving the FDA approval.  Full Article

Jiangsu Hengrui Medicine passes FDA approval
Thursday, 10 May 2018 

May 10 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it received approval for its drug Thiotepa for injection, which is used for treatment of breast cancer, ovarian cancer and other lymphoma, from U.S Food and Drug Administration .  Full Article

Jiangsu Hengrui Medicine announces 2017 dividend payment
Monday, 16 Apr 2018 

April 16(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it plans to pay cash dividend of 1.30 yuan per 10 shares (before tax), distribute two new shares for every 10 shares as stock dividends, and use additional paid-in capital to distribute one new share for every 10 shares, as the dividend payment plan for 2017.  Full Article

Jiangsu Hengrui Medicine to invest 610.7 mln yuan in medical firm
Monday, 16 Apr 2018 

April 16(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it plans to invest 610.7 million yuan in a Chengdu-based medical firm, and will increase stake in the medical firm to 95.9 percent from 84 percent .  Full Article

Jiangsu Hengrui Medicine announces change in accounting policy
Monday, 16 Apr 2018 

April 16(Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>:Says it changes accounting policy based on accounting standards for business enterprises.  Full Article

Jiangsu Hengrui Medicine's 2017 Net Profit Up 24.25 Pct Y/Y
Sunday, 15 Apr 2018 

April 15 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::SAYS 2017 NET PROFIT UP 24.25 PERCENT Y/Y AT 3.22 BILLION YUAN ($513.35 million).  Full Article

TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES.TG THERAPEUTICS INC - ‍ UNDER TERMS, HENGRUI WILL RECEIVE AN UP-FRONT LICENSING FEE AND NEAR-TERM MILESTONES, PAYABLE IN TG COMMON STOCK​.TG THERAPEUTICS INC - ‍HENGRUI IS ELIGIBLE TO RECEIVE COLLABORATION AND LICENSING PAYMENTS OF ABOUT $350 MILLION, IN ADDITION TO ROYALTIES ON FUTURE SALES​.  Full Article

China stocks climb as survey shows steady services growth

SHANGHAI, June 5 China stocks firmed on Tuesday, after a private survey showed the services sector expanded at a steady pace in May, while pharmaceutical sector gained the most. ** The blue-chip CSI300 index rose 1.0 percent to 3,845.32, while the Shanghai Composite Index ended up 0.7 percent at 3,114.21. ** China's services sector expanded at a solid pace last month, with companies accelerating hiring on the back of the strongest optimism for future growth in 11 months, the survey s